This article is mentioned in:

Introduction

Dilated cardiomyopathy (DCM) is a common type of non-ischemic cardiomyopathy, which leads to progressive heart failure and sudden cardiac-associated mortality (1–3). DCM is characterized by ventricular chamber enlargement and systolic dysfunction, and has strong associations with cardiac development, organ morphology, myocardial energy metabolism and abnormal gene expression (4,5). In patients with DCM, the possible causes of the condition are often ascribed to coronary artery disease, hypertension, viral infections and alcohol abuse (6). However, the exact mechanisms involved in the development of DCM remain unknown.

Long noncoding RNAs (lncRNAs) are a cluster of transcribed RNAs with a length >200 nucleotides, which lack protein-coding potential (7,8). lncRNAs function by regulating their neighboring or distant target genes through connection with microRNAs and interaction with proteins (9,10). Previous studies have verified that lncRNAs serve critical roles in the progression of cardiovascular diseases by modulating cardiac development, homeostasis and regeneration (7,11–14). Nevertheless, determining the genome-wide profile is urgently required to uncover the expression variation and potential functions of lncRNAs in the development of DCM.

In the present study, the genome-wide profile of circulating lncRNAs between patients with DCM and controls was detected by RNA sequencing, which is considered as a credible method to define lncRNA expression (15–17). Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and lncRNA-messenger RNA (mRNA) co-expression network analysis were performed to explore the potential functions of differentially expressed lncRNAs in DCM.

Materials and methods

Ethical statement

All procedures in the present study were approved by the Ethics Committee of the Liaocheng People's Hospital (Liaocheng, China). All subjects provided written informed consent prior to enrollment into the study.

Study subjects

The 8 control patients who admitted for routine testing and 8 patients with DCM underwent internal medical treatment were enrolled in the present study at Liaocheng People's Hospital between July 2015 and May 2016 (Table I). The inclusion criteria for patients with DCM were as follows: i) Left ventricular end-diastolic diameter (LVED) of >50 mm (females) or >55 mm (males); and ii) left ventricular ejection fraction (LVEF) of <45% and/or left ventricular fraction shortening of <25%. Patients with clear causes of idiopathic DCM, including hypertension, coronary artery diseases, valvular disease, congenital defect, alcoholic cardiomyopathy, tachycardia-induced cardiomyopathy and peripartum cardiomyopathy, were excluded from the present study. Patients with a positive family history of DCM were also excluded. The following data were gathered for the DCM and control subjects: Sex, age, blood pressure on admission, heart rate, New York Heart Association classes (18), LVED, LVEF, N-terminal pro b-type natriuretic peptide, medical history and diagnostic testing (Table I).

Table I. Clinical characteristics of control subjects and DCM patients.

Table I.

Clinical characteristics of control subjects and DCM patients.

	Controls (n=8)								DCM patients (n=8)
Group	1	2	3	4	5	6	7	8	1	2	3	4	5	6	7	8
Sex	M	M	M	M	F	M	M	M	M	M	M	M	F	M	M	M
Age (years)	32	38	35	35	61	60	46	35	33	40	33	36	63	61	47	34
SBP (mmHg)	110	120	112	118	124	122	126	118	140	120	110	108	104	102	102	124
DBP (mmHg)	72	74	70	74	74	80	82	72	90	80	70	72	76	70	86	78
Heart rate (rpm)	66	68	72	65	73	67	76	74	105	86	98	85	72	105	78	90
LVED (mm)	46	44	41	46	44	47	43	44	56	63	67	78	84	62	68	75
LVEF (%)	68	61	68	66	65	73	77	68	42	26	20	16	19	25	30	27
NT-proBNP (pg/ml)	70	82	60	84	96	90	88	78	5,400	6,630	1,470	2,450	2,980	1,760	2,530	2,228
NYHA class	–	–	–	–	–	–	–	–	IV	III	III	III	IV	IV	IV	III

[i] DCM, dilated cardiomyopathy; M, male; F, female; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVED, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association.

Specimen collection

Blood samples for RNA sequencing were collected from 8 typical patients with DCM and 8 healthy controls. In addition, blood samples from another 20 patients with DCM (16 males and 4 females, 43.2±8.7 years old) and 20 healthy controls (16 males and 4 females, 45.3±7.9 years old) were collected to identify the expression levels of the top 10 lncRNAs with the highest degree via Reverse transcription-polymerase chain reaction (RT-PCR), which was conducted as described below. All the patients were diagnosed with DCM by two experienced clinicians and underwent internal medical treatment at Liaocheng People's Hospital based on the American Heart Association guidelines (19,20). Peripheral venous blood (5 ml) samples were collected from all participants in sterile tubes with ethylenediaminetetraacetic acid.

RNA isolation, library construction and sequencing

Total RNA was isolated and enriched using TRIzol® reagent (cat. no. 15596; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Next, ribosomal RNA was removed using the Ribo-Zero rRNA Removal kit (cat. no. MRZB12424; Illumina, Inc., San Diego, CA, USA). Ribosomal RNA-depleted RNAs were used to construct RNA libraries with the TruSeq Stranded Total RNA Library Prep kit (cat. no. RS-122-2301; Illumina, Inc.). Libraries were controlled for quality and quantified using the Agilent BioAnalyzer 2100 system (cat. no. 5067-1505; Agilent Technologies Inc., Santa Clara, CA, USA). Libraries (10 pM) were denatured as single-stranded DNA molecules, captured on Illumina flow cells, amplified in situ as clusters and finally sequenced for 150 cycles on the Illumina HiSeq sequencer (HiSeq 4000; Illumina, Inc.). All these procedures were conducted according to the manufacturer's protocol.

Analysis of RNA sequencing data

Paired-end reads were harvested from Illumina HiSeq sequencer and quality controlled by Q30 (P<0.001). Subsequent to removing the 3′ adaptor-trimming and low-quality reads with cutadapt software (version 1.9.3, http://cutadapt.readthedocs.io/en/stable/index.html), the high-quality trimmed reads were aligned to the reference genome (UCSC hg19) guided by the Ensembl Gff gene annotation file with HISAT2 software (version 2.0.4, http://ccb.jhu.edu/software/hisat2/index.shtml). The cuffdiff software (version 2.2.1; part of Cufflinks, http://cole-trapnell-lab.github.io/cufflinks/cuffdiff/index.html) was then used to obtain the expression profiles of lncRNAs and mRNAs in terms of the fragments per kilobase of transcript per million fragments mapped (FPKM). Next, the fold-change (FC) and P-values were calculated based on the FPKM, and differentially expressed lncRNAs and mRNAs were identified between the DCM and control groups. The criteria were set as an FC of ≥2 or ≤-2, and a P-value of <0.05 between two groups. P-values were corrected with the false discovery rate method. Hierarchical clustering with average linkage was used to calculate the distinguishable expression patterns. RNA sequencing data were uploaded to the Gene Expression Omnibus database (accession no. GSE101585; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?&acc=GSE101585).

RT-PCR

Total RNA from the blood samples was isolated and enriched with TRIzol® reagent (Thermo Fisher Scientific, Inc.), and then the concentration was measured with a NanoDrop ND-1000 spectrophotometer (Nanodrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, MA, USA). Total RNA was reverse transcribed into cDNA with the SuperScript III reverse transcriptase (cat. no. 18080044; Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, 2X PCR master mix (CloudSeq Biotech, Inc., Shanghai, China) was applied to perform the PCR with the target RNAs and internal reference, β-actin (ACTB) of the samples. The primers were as follows: TCONS_00028585, forward: 5′-CGCAGAAGCACAGGGTTAAT-3′, reverse, 5′-GCTGTAGCTTGCTGGCTCTT-3′; ENST00000439796, forward, 5′-TGAAAAACACCGCAGTCAAA-3′, reverse, 5′-AGGCCCTAAAGAAGGCCATA-3′; TCONS_l2_00009351, forward, 5′-ATGAAGCTGGGCAAATCAGT-3′, reverse, 5′-AGATGGCACAAATGCTCTCC-3′; ENST00000448134, forward 5′-TTGGTGGACGGAACAGTGTA-3′, reverse, 5′-GAGTTAGCCAGTGGGGTGAA-3′; ENST00000607876, forward, 5′-CCCTCACACCTCTGTGTCCT-3′, reverse, 5′-GTGACACAGCCACAGTCCAC-3′; and ACTB, forward, 5′-GTGGCCGAGGACTTTGATTG-3′ and reverse, 5′-CCTGTAACAACGCATCTCATATT-3′.

The thermal cycling conditions were set to 40 cycles at 95°C for 10 sec and 60°C for 60 sec, following predegeneration for 10 min at 95°C. Data were analyzed using the 2−∆∆Cq method (21,22).

Functional group analysis

The cis target genes were analyzed through the gene annotations provided by the University of California (Oakland, CA, USA) (23), and trans target genes were predicted using BLAT (24). GO analysis, which contained three domains, namely the ‘biological process’, ‘cellular component’ and ‘molecular function’, was performed to explore the functions of differentially expressed coding genes with the Database for Annotation, Visualization and Integrated Discovery (http://david.abcc.ncifcrf.gov) (25). Pathway analysis was also adopted to explore potential pathways of differentially expressed coding genes, according to KEGG pathways (https://www.genome.jp/kegg/). The criteria were set as follows: Fold-change of ≥2 or ≤-2, and P-value of <0.05 between the DCM and control groups.

Analysis of the lncRNA-mRNA co-expression network

Pearson's correlation coefficient (PCC) was calculated for each of the lncRNA-mRNA pairs across the DCM and control groups. Co-expressed lncRNA-mRNA pairs with PCC>0.99 and P<0.01 were selected. In total, two lncRNA-mRNA co-expression networks were initially constructed based on co-expressed lncRNA-mRNA pairs in the DCM and control groups. The ‘lost’ network presents the lncRNA-mRNA co-expression pairs, which only appeared in the control group, and the ‘obtained’ network presents the co-expression pairs, which only appeared in the DCM group. Finally, the dynamic lncRNA-mRNA co-expression network was constructed by combining the ‘lost’ and ‘obtained’ networks. Subsequently, key lncRNA nodes were identified in the combined network. According to the mRNAs paired with key lncRNAs, GO analysis was performed to separately identify the significantly enriched biological processes in the DCM and the normal co-expression networks. P<0.05 was considered to indicate a statistically significant difference.

Results

Overview of lncRNAs between patients with DCM and controls determined by RNA sequencing

RNA sequencing detected a total of 88,768 lncRNAs in the serum of DCM and control subjects. In order to assess the differentially expressed lncRNAs, the criteria were set as fold-change of ≥2 or ≤-2, and P-value of <0.05 between the DCM and control groups. A hierarchical clustering approach was adopted to verify the consistency in the specimens, according to dysregulated lncRNAs (Fig. 1A). A heat map of partially dysregulated lncRNAs is presented in Fig. 1B. Compared with the control group, 998 dysregulated lncRNAs were identified in patients with DCM, including 661 unregulated lncRNAs and 327 downregulated lncRNAs (Fig. 1C). In addition, a scatter plot was implemented to identify differentially expressed lncRNAs between DCM and control subjects (Fig. 1D).

Figure 1. Overview of lncRNAs differentially expressed between 8 patients with DCM and 8 controls, detected by RNA sequencing. (A) Hierarchical clustering of partial differentially expressed lncRNAs. (B) Heat map of partially dysregulated lncRNAs. (C) A total of 88,768 lncRNAs were detected by RNA sequencing. Among these, 988 lncRNAs were differentially expressed between patients with DCM and controls, including 661 upregulated and 327 downregulated lncRNAs. (D) A scatter plot of the total lncRNAs between patients with DCM and controls. The criteria used included a fold-change of ≥2 or ≤-2, and a P-value of <0.05. Ctrl, control; DCM, dilated cardiomyopathy; lncRNA, long noncoding RNA.

Distribution profiles of differentially expressed lncRNAs

The dysregulated lncRNAs were subsequently classified in five categories based on their genomic locations, which included intergenic (n=654), bidirectional (n=220), exonic (n=25), antisense (n=6) and intronic (n=5) lncRNAs (Fig. 2A). In terms of length distribution, dysregulated lncRNAs ranged mainly between 500 and 10,000 base pairs (bp; Fig. 2B). These differentially expressed lncRNAs were scattered throughout the human chromosomes (Fig. 2C).

Figure 2. Distribution profiles of dysregulated lncRNAs. (A) Class distribution of dysregulated lncRNAs, including 654 intergenic, 220 bidirectional, 25 exonic, 6 antisense and 5 intronic lncRNAs. (B) Length distribution of dysregulated lncRNAs, which were mainly between 500 and 10,000 bp in length. (C) Chromosomal distribution of dysregulated lncRNAs. bp, base pairs; Chr, chromosome; lncRNA, long noncoding RNA.

RT-PCR validation of differentially expressed lncRNAs

The top 10 upregulated lncRNAs presenting the highest fold-change were TCONS_00028585, ENST00000439796, TCONS_l2_00009351, ENST00000448134, ENST00000607876, TCONS_00015639, ENST00000489016, TCONS_00011165, ENST00000322227 and ENST00000458361. The top 10 downregulated lncRNAs presenting the highest fold-change were TCONS_00003609, TCONS_00018640, ENST00000606664, uc003uey.1, ENST00000494231, ENST00000419628, ENST00000435049, ENST00000609755, TCONS_00026839 and ENST00 000500180 (Fig. 3A). Next, five dysregulated lncRNAs were selected to confirm the lncRNA expression, including TCONS_00028585 (Fig. 3B), ENST00000439796 (Fig. 3C), TCONS_l2_00009351 (Fig. 3D), ENST00000448134 (Fig. 3E) and ENST00000607876 (Fig. 3F). The results verified that the expression levels of these lncRNAs were significantly upregulated in DCM patients as compared with those in control subjects.

Figure 3. Partial dysregulated lncRNAs and validation of the results of RNA sequencing. (A) Top 10 upregulated and top 10 downregulated lncRNAs with the highest fold-change between patients with DCM (n=8) and controls (n=8). Reverse transcription-polymerase chain reaction validation of five differentially expressed lncRNAs was conducted, including (B) TCONS_00028585, (C) ENST00000439796, (D) TCONS_l2_00009351, (E) ENST00000448134 and (F) ENST00000607876. The experiments were repeated for three times. *P<0.05 and **P<0.01, vs. Ctrl group. lncRNA, long noncoding RNA; DCM, dilated cardiomyopathy; Ctrl, control.

GO and KEGG pathway analyses of dysregulated lncRNAs

In order to assess the potential functions of these dysregulated lncRNAs, GO and KEGG pathway analyses were performed with the target coding genes of downregulated lncRNAs and upregulated lncRNAs, separately. GO analysis was comprised of three networks, including the ‘biological process’, ‘cellular component’ and ‘molecular function’. Through GO analysis of neighbor coding genes, the downregulated lncRNAs were found to be mostly enriched as follows: System development, anatomical structure development and cellular component organization in the ‘biological process’ analysis (Fig. 4A); organelle, intracellular organelle and intracellular part in the ‘cellular component’ analysis (Fig. 4B); and protein binding, cytoskeletal protein binding and enzyme binding in the ‘molecular function’ analysis (Fig. 4C). KEGG pathway analysis revealed that downregulated lncRNAs were mainly associated with gap junction, hypertrophic cardiomyopathy, phagosomes and DCM pathways (Fig. 4D). In addition, upregulated lncRNAs were mainly associated with the regulation of metabolic process, organ morphogenesis and regulation of nucleobase-containing compound metabolic process in the biological process analysis (Fig. 5A), with the cell projection, cell junction and intracellular part in the ‘cellular component’ analysis (Fig. 5B), and with protein binding, enzyme binding and calcium ion transmembrane transporter activity in the ‘molecular function’ analysis (Fig. 5C). The upregulated lncRNAs exhibited a strong association with hypertrophic cardiomyopathy and various cancer pathways, according to KEGG pathway analysis (Fig. 5D).

Figure 4. GO and KEGG pathway analyses were performed for protein-coding neighbors of downregulated lncRNAs. GO analysis results of downregulated lncRNAs according to (A) ‘biological process’, (B) ‘cellular component’ and (C) ‘molecular function’. (D) Pathway analysis results of downregulated lncRNAs based on the KEGG database. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; lncRNA, long noncoding RNA.

Figure 5. GO and KEGG pathway analyses were performed for protein-coding neighbors of upregulated lncRNAs. GO analysis results of upregulated lncRNAs according to (A) ‘biological process’, (B) ‘cellular component’ and (C) ‘molecular function’. (D) Pathway analysis results of upregulated lncRNAs based on the KEGG database. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; lncRNA, long noncoding RNA.

Overview of mRNAs between patients with DCM and controls determined by RNA sequencing

By RNA sequencing, a total of 1,418 differentially expressed mRNAs (800 upregulated mRNAs and 618 downregulated mRNAs) were identified among the 20,315 detected mRNAs between the DCM and control groups (Fig. 6A), according to the criteria of a fold-change of ≥2 or ≤-2, and P<0.05. A scatter plot was implemented to identify the differentially expressed mRNAs (Fig. 6B). The top 10 upregulated mRNAs were DCAF15, DEPDC4, RASA4, ZNF227, ZNF559-ZNF177, POLR1C, TES, KCNIP2, RAD52 and CD300LF. The top 10 downregulated mRNAs were HLA-A, PHB, SNRPN, DPEP2, OR6S1, ZNF233, DUT, ACD, KIAA1324 and C11orf48 (Fig. 6C).

Figure 6. Overview of mRNAs differentially expressed between patients with DCM (n=8) and controls (n=8), determined by RNA sequencing. (A) Brief RNA sequencing results of mRNAs. A total of 20,315 mRNAs were detected from the mRNA expression profile analysis. Among these, 1,418 mRNAs were differentially expressed between patients with DCM and controls, including 800 upregulated and 618 downregulated mRNAs. (B) Scatter plot of mRNAs. The criteria included a fold-change of ≥2 or ≤-2, and a P-value of <0.05. (C) Top 10 upregulated and top 10 downregulated mRNAs with the highest fold-change. mRNA, messenger RNA; DCM, dilated cardiomyopathy.

lncRNA-mRNA co-expression network analysis

A dynamic lncRNA-mRNA co-expression network was constructed based on the PCC to identify the correlation between differentially expressed lncRNAs and mRNAs. Initially, the DCM and control lncRNA-mRNA co-expression networks were constructed individually. A total of 1,331 lncRNA-mRNA pairs were detected in the DCM co-expression network (‘obtained’ network), while 1,348 lncRNA-mRNA pairs were identified in the control co-expression network (‘lost’ network). Next, the two networks were combined into a total co-expression network containing 676 nodes (69 lncRNA nodes and 607 mRNA nodes) and 2,661 edges (Fig. 7). The top 10 lncRNA nodes (hub nodes) with the highest degree were XLOC_004581, XLOC_l2_010969, ENSG00000202198, ENSG00000251408, XLOC_008043, BC015774, ENSG00000267172, AK055324, AK094644 and CEP83-AS1 (Fig. 8A).

Figure 7. Schematic of the construction process of the lncRNA-mRNA co-expression network between patients with DCM and controls. Two lncRNA-mRNA co-expression networks were initially constructed based on co-expressed lncRNA-mRNA pairs in each sample group. Next, the ‘lost’ and ‘obtained’ networks were identified based on the two networks, which included pairs appearing only in normal and DCM samples, respectively. The dynamic lncRNA-mRNA co-expression network was constructed by connecting the ‘lost’ and ‘obtained’ networks. DCM, dilated cardiomyopathy; lncRNA, long noncoding RNA; mRNA, messenger RNA.

Figure 8. Analysis of lncRNA-mRNA co-expression network between patients with DCM and controls. (A) Top 10 lncRNA nodes with the highest degree. (B) Reverse transcription-polymerase chain reaction assay of blood samples from another 20 patients with DCM and 20 healthy controls, used to identify the expression levels of the top 10 lncRNAs with the highest degree. The experiments were repeated for three times. Biological processes associated with the top 10 lncRNA-mRNA co-expression pairs in the (C) DCM and (D) control groups are presented. DCM, dilated cardiomyopathy; lncRNA, long noncoding RNA; mRNA, messenger RNA.

Furthermore, the blood samples from another 20 patients with DCM and 20 healthy controls were collected to identify the expression levels of the top 10 lncRNA nodes with the highest degree using RT-PCR assay (Fig. 8B). According to the GO analysis, the top 10 lncRNA-mRNA co-expression pairs with the highest degree were mainly associated with positive regulation of cyclin-dependent protein serine/threonine kinase activity, translational initiation, DNA-templated transcription and regulation of muscle cell differentiation in the DCM group (‘obtained’ network; Fig. 8C), and with negative regulation of apoptotic process, nuclear-transcribed mRNA catabolic process and response to stress in the control group (‘lost’ network; Fig. 8D). Finally, an lncRNA-mRNA co-expression network was constructed in order to identify the target mRNAs of the top 10 lncRNA nodes with the highest degree (Fig. 9).

Figure 9. Co-expression network with the top 10 lncRNA nodes with the highest degree in the dynamic lncRNA-mRNA co-expression network. Target mRNAs of the top 10 lncRNAs with the highest degrees are shown in the lncRNA-mRNA co-expression network. The red nodes represent lncRNAs, and the pink nodes represent mRNAs. lncRNA, long noncoding RNA; mRNA, messenger RNA.

Discussion

In the present study, a genome-wide analysis of dysregulated circulating lncRNAs between patients with DCM and controls was performed by RNA sequencing. Subsequently, the study attempted to elucidate the potential mechanism of DCM with bioinformatics analysis. A total of 998 dysregulated lncRNAs and 1,418 differentially expressed mRNAs were identified between patients with DCM and controls. Among these dysregulated lncRNAs, the expression levels of several upregulated lncRNAs were verified with RT-PCR; the expression levels of downregulated lncRNAs in DCM should be conducted in the future. These lncRNAs were mainly intergenic and bidirectional lncRNAs distributed among all human chromosomes, with lengths mainly ranging between 500 and 10,000 bp. Bioinformatics analysis revealed that the dysregulated lncRNAs exhibited a strong association with system development, organ morphogenesis and metabolic regulation in the ‘biological process’ analysis. It was also observed that several potential pathways, including the gap junction pathway, phagosome, and dilated and hypertrophic cardiomyopathy pathways, may serve crucial roles in the genesis and development of DCM. Through the biological analysis of the top 10 lncRNA-mRNA pairs with the highest degree in the dynamic lncRNA-mRNA co-expression network, it was observed that the top 10 lncRNAs were mainly associated with DNA-templated transcription, translational initiation and regulation of muscle cell differentiation in the DCM group. However, these top 10 lncRNAs were associated with the negative regulation of apoptotic process, nuclear-transcribed mRNA catabolic process and regulation of response to stress in the control group.

Due to the severe outcome of patients with DCM, it is imperative to uncover effective biomarkers and therapy targets for the diagnosis and treatment of this disease. lncRNAs are implicated in diverse biological processes in different diseases, such as in cell-cycle control, differentiation, apoptosis, chromatin remodeling, maintenance of the nuclear structure integrity, and transcriptional and post-transcriptional processing (26–29). Recent studies have demonstrated that lncRNAs serve critical roles in cardiac development, and participate in cardiac homeostasis and regeneration as epigenetic regulators of cardiac gene expression (11,13,30). Circulating lncRNAs have also been reported to be involved in the pathophysiology of cardiovascular diseases. For instance, the circulating lncRNA HOTAIR performed a protective role in acute myocardial infarction via the negative regulation of miR-1 (31). Although a few pathogenic lncRNAs have been reported in DCM (32–34), the majority of these studies did not employ RNA sequencing tools and bioinformatics analysis; therefore, more comprehensive information remains to be elucidated. In the present study, the genome-wide profile of lncRNAs was identified by comparing their expression in the serum of patients with DCM and controls by RNA sequencing. The present study identified the lncRNA variation in DCM and provides a critical insight on the potential mechanisms underlying this disease. In addition, the present results are important for the identification of novel biomarkers of idiopathic DCM.

Cardiac sarcomere proteins are vitally important in maintaining a normal cardiac structure. Mutations of the genes encoding these proteins, particularly the titin and myosin heavy chain 7 genes, may result in the occurrence of DCM (35–38). In the present study, it was observed that the titin gene was regulated by several lncRNAs, including ENGS00000237298, ENGS00000267784, ENGS00000442329, ENGS00000603415 and ENGS00000603521. In addition, the myosin heavy chain 7 gene was regulated by NR126491. These results suggested the potential regulatory mechanisms of these sarcomere proteins, although mutations in sarcomeric genes were not examined in the present study. Furthermore, more potential genes were identified at the genome-wide level, which may function as key regulators in the development of DCM.

The lncRNA-mRNA co-expression network analysis was performed by combining lncRNA-mRNA pairs identified separately in the DCM and control groups. Biological processes were analyzed with the target mRNAs of the top 10 lncRNA nodes with the highest degree in the DCM and control groups. The function of the majority of these lncRNAs remain unknown, apart from ENSG00000202198 (also known as RN7SK), which was identified to be associated with immunodeficiency syndrome (39). Notably, these 10 lncRNAs participated in different biological processes between the DCM and control groups. It is known that lncRNAs are able to regulate multigene expression to participate in biological processes (9,10). The findings of the present study suggested that lncRNAs were also able to change their main target genes, according to different disease circumstances. Modifying the cardiac circumstances of patients with DCM may be an effective therapy to relieve the progression of this disease.

In conclusion, the present study identified the genome-wide profile of lncRNAs in DCM by RNA sequencing. Bioinformatics analysis identified the potential functions of these lncRNAs. The lncRNA-mRNA co-expression network analysis revealed that the main target genes were different in DCM. Although the study mainly focused on bioinformatics analysis without experimental confirmation of the pathophysiology in DCM, the findings offered a novel insight into the disease pathogenesis and provided a theoretical basis for future studies of lncRNAs in DCM.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81573095).

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in the Gene Expression Omnibus database (accession no. GSE101585; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?&acc=GSE101585).

Authors' contributions

GH, WY and JL designed the study and conducted the experiments. CY and YX contributed to the data acquisition and collection. YW, JW and MC were responsible for analyzing and interpreting the data. GH, WY and JL drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures in the present study were approved by the Ethics Committee of the Liaocheng People's Hospital.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References